Unaudited Condensed Interim Financial Statements of

PENDER GROWTH FUND INC.

Three months ended March 31, 2023

NOTICE OF NO AUDITOR REVIEW OF THE INTERIM FINANCIAL STATEMENTS

PenderFund Capital Management Ltd., the Manager of the Pender Growth Fund Inc. (the "Company"), appoints an independent auditor to audit the Company' Annual Financial Statements. In accordance with Canadian securities laws (National Instrument 51-102 "Continuous Disclosure Obligations"), the Manager must disclose if an auditor has not reviewed the interim Financial Statements.

The Company' independent auditor has not performed a review of these Interim Financial Statements in accordance with standards established by the Chartered Professional Accountants of Canada.

Condensed Interim Statements of Financial Position (Unaudited)

	Notes	March 31, 2023	December 31, 2022
Assets	Notes	2023	2022
Cash		\$ 2,739,568 \$	1,552,667
Income taxes receivable	13	3,502,595	3,502,595
Due from related parties	5	3,496,336	3,023,368
Divestment proceeds receivable		-	1,916,139
Prepaid expenses		12,569	6,770
Interest receivable		4,247	162,932
Investments	4, 12	61,944,202	66,299,539
Total assets		71,699,517	76,464,010
Liabilities			
Interest payable		27,709	31,864
Payable for investments purchased		28,356	-
Share repurchase payable		21,080	13,186
Accounts payable and accrued liabilities		172,383	142,880
Deferred income tax liability	13	872,402	1,536,825
Loan payable	10	3,750,000	4,500,000
Total liabilities		4,871,930	6,224,755
Shareholders' equity			
Class C Common shares:			
Contributed capital	8	17,323,932	17,442,542
Retained earnings		49,503,655	52,796,713
Total Shareholders' Equity		\$ 66,827,587 \$	70,239,255
Number of shares outstanding	8	7,553,629	7,569,929
Total shareholders' equity per share		\$ 8.85 \$	9.28
Subsequent events	15		

The accompanying notes are an integral part of these financial statements.

Approved on behalf of the Board of Directors:

"David Barr"

Director

"Kelly Edmison" Director

Condensed Interim Statements of Comprehensive Income (Unaudited)

			Three months ended	Three months ended
	Notes		March 31, 2023	March 31, 2022
Revenue:				
Interest income (reversal)	6	\$	(139,904) \$	3.642
Foreign exchange loss		•	(1,749)	(13,580)
Changes in fair value of investments:			(1,1,1,2)	(,)
Net realized loss			(1,027,396)	(3,797,801)
Net change in unrealized depreciation			(2,477,313)	(53,825,471)
Total revenue			(3,646,362)	(57,633,210)
Operating Expenses:				
Management fees	5		169,397	240.065
Administration expenses			91,730	123,522
Interest and financing expenses	10		85,080	289,545
Audit and professional fees			39,510	91,709
Directors' fees			12,610	12,584
Custody and recordkeeping fees			4,258	8,341
Legal fees			3,238	12,584
Transaction costs			572	11,077
Total operating expenses			406,395	789,427
Net operating loss		\$	(4,052,757) \$	(58,422,637)
Other Items:				
Performance fees	5		(567,958)	(14,943,990)
Fees waived by the Manager	5		141,990	5,940,727
Net amount			(425,968)	(9,003,263)
Amount of Pender Private Investments				() , ,
Inc.'s ("PPI") performance fee earned by				
the Manager attributable to the				
Company's ownership of PPI shares	5		330.692	10,957,911
Total performance fee adjustment	5		(95,276)	1,954,648
Net loss before income tax recovery		\$	(3,957,481) \$	(60,377,285)
		φ	(3,957,461) \$	(00,377,205)
Deferred income tax recovery	13		(664,423)	(8,555,580)
Net loss		\$	(3,293,058) \$	(51,821,705)
Net loss, per share:		•	(0.4.1)	(0.04)
Class C shares		\$	(0.44) \$	(6.81)
Weighted average number of non-redeemable			;	
Class C shares outstanding			7,565,854	7,606,429

The accompanying notes are an integral part of these financial statements.

Condensed Interim Statements of Changes in Equity (Unaudited)

Class C shares	Note	Three months ended March 31, 2023	Three months ended Aarch 31, 2022
Balance, beginning of period		\$ 70,239,255 \$	198,643,655
Net loss		(3,293,058)	(51,821,705)
Capital transactions	8(b)	(118,610)	(335,644)
Balance, end of period		\$ 66,827,587 \$	146,486,306

The accompanying notes are an integral part of these financial statements.

Condensed Interim Statements of Cash Flows (Unaudited)

	Three months ended March 31, 2023	Three months ended March 31, 2022
Cash (used in) provided by:		
Operating:		
Net loss	\$ (3,293,058) \$	(51,821,705)
Adjustments for:		
Interest income (reversal)	139,904	(3,642)
Foreign exchange loss	1,749	13,580
Net realized loss on sales of investments	1,027,396	3,797,801
Net change in unrealized depreciation on investments	2,477,313	53,825,471
Increase in income taxes receivable	-	(68,874)
(Increase) decrease in due from related parties	(472,968)	1,912,211
Decrease in divestment proceeds receivable	1,916,139	66,944
(Increase) decrease in prepaid expenses	(5,799)	5,014
(Decrease) increase in interest payable	(4,155)	192,966
Increase in accounts payable and accrued liabilities	29,503	40,289
Decrease in deferred income tax liability	(664,423)	(8,555,580)
Decrease in income taxes payable	-	(3,031,126)
	1,151,601	(3,626,651)
Proceeds on disposal of investments	2,383,797	7,657,560
Purchase of investments	(1,504,813)	(11,003,591)
	878,984	(3,346,031)
Interest received	18,781	-
Net cash (used in) provided by operating activities	2,049,366	(6,972,682)
Financing:		
Repayment of loan payable	(750,000)	-
Repurchase of shares	(110,716)	(321,968)
Net cash (used in) provided by financing activities	(860,716)	(321,968)
Net increase (decrease) in cash during the period	1,188,650	(7,294,650)
Cash, beginning of period	1,552,667	10,008,858
Effect of exchange rate fluctuations on cash	(1,749)	(13,580)
Cash, end of period	\$ 2,739,568 \$	2,700,628

The accompanying notes are an integral part of these financial statements.

Condensed Interim Schedule of Investment Portfolio (Unaudited)

As at March 31, 2023

Exercise price	1	Issue	Number of shares/		
Interest rat	e Expiry date	Currency	Units/Face value	Cost	Fair value
Publicly listed companies: (14.3%)					
Common shares: (14.3%)					
BuildDirect.com Technologies Inc.			428,240	1,969,904	77,08
Copperleaf Technologies Inc. ¹ ("Copperleaf")			232,342	673,792	1,277,88
GreenSpace Brands Inc.			69.193.248	3,845,233	345.96
Peloton Interactive, Inc.			102,875	4,983,561	1,576,66
ProntoForms Corporation			3,052,333	1,581,876	1,556,69
Quorum Information Technologies Inc.			1,683,100	1,461,268	1,077,18
Sangoma Technologies Corporation			289,843	5,525,295	1,472,40
Tantalus Systems Holding Inc.			523,751	279,556	419,00
Zillow Group, Inc.			29,090	2,156,222	1,748,34
			29,090	22,476,707	9,551,21
Varrants: (0.0%)				22,470,707	0,001,21
BuildDirect.com Technologies Inc. 4.23	12/31/2030	USD	89,722	-	
BuildDirect.com Technologies Inc. 6.90		CAD	428,240	-	
GreenSpace Brands Inc. 0.09	09/28/2023	CAD	612,300	-	
!			,	-	
_oans (0.0%)		0.15	4 004 477	000.000	
GreenSpace Brands Inc. 12.009	6 07/01/2023	CAD	1,031,177	800,000	
				00 070 707	0 554 04
Private unlisted companies: (78.4%)				23,276,707	9,551,21
Common shares/Units:					
Pender Private Investments Inc., Commercialization	Shares ² ("PPI")		1.002.555	508,096	
Pender Private Investments Inc., Legacy Shares ² ("P			6,452,726	17,980,400	
Pender Technology Inflection Fund II Limited Partner			-	1,746,406	
Tiny Capital Ltd.	····p (· · · · ·)		2,513	1,000,174	
Preferred shares:					
			00.070	000.000	
Checkfront, Inc., Series A-2			38,973	999,993	
Clarius Mobile Health Corp., Series A1			1,287,055	1,145,479	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2			1,287,055 365,256	1,145,479 499,999	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.)			1,287,055 365,256 51,295	1,145,479 499,999 1,999,992	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc.			1,287,055 365,256 51,295 103,823	1,145,479 499,999 1,999,992 4,055,326	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc.			1,287,055 365,256 51,295 103,823 629,232	1,145,479 499,999 1,999,992 4,055,326 914,400	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc.			1,287,055 365,256 51,295 103,823	1,145,479 499,999 1,999,992 4,055,326	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc. Convertible Loans:			1,287,055 365,256 51,295 103,823 629,232 585,179	1,145,479 499,999 1,999,992 4,055,326 914,400 914,400	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc.	6 03/01/2025		1,287,055 365,256 51,295 103,823 629,232	1,145,479 499,999 1,999,992 4,055,326 914,400	
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc. Convertible Loans:	6 03/01/2025		1,287,055 365,256 51,295 103,823 629,232 585,179	1,145,479 499,999 1,999,992 4,055,326 914,400 914,400	52,392,98
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc. Convertible Loans: Checkfront, Inc. 10.00%			1,287,055 365,256 51,295 103,823 629,232 585,179	1,145,479 499,999 1,999,992 4,055,326 914,400 914,400 500,000	52,392,98
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc. Convertible Loans: Checkfront, Inc. 10.00%			1,287,055 365,256 51,295 103,823 629,232 585,179	1,145,479 499,999 1,999,992 4,055,326 914,400 914,400 500,000 32,264,665	, , ,
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc. Convertible Loans: Checkfront, Inc. 10.00%			1,287,055 365,256 51,295 103,823 629,232 585,179 500,000	1,145,479 499,999 1,999,992 4,055,326 914,400 914,400 500,000 32,264,665 (13,122)	61,944,20
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc. Convertible Loans: Checkfront, Inc. 10.009 Less: Transaction costs included in cost of investment Total investments (92.7%) Cash (4.1%)			1,287,055 365,256 51,295 103,823 629,232 585,179 500,000	1,145,479 499,999 1,999,992 4,055,326 914,400 914,400 500,000 32,264,665 (13,122)	61,944,20
Clarius Mobile Health Corp., Series A1 Clarius Mobile Health Corp., Series A2 DistillerSR Inc. (Formerly Evidence Partners Inc.) Jane Software Inc. Traction Complete Technologies Inc. Traction Rec Technologies Inc. Convertible Loans:			1,287,055 365,256 51,295 103,823 629,232 585,179 500,000	1,145,479 499,999 1,999,992 4,055,326 914,400 914,400 500,000 32,264,665 (13,122)	52,392,98 61,944,203 2,739,56 2,143,81 66,827,58

The accompanying notes are an integral part of these financial statements.

¹Copperleaf is the Company's largest single public company holding, representing 60.0% of the total portfolio, including both its direct holdings and its indirect holdings investment through its investment in Pender Private Investments Inc.

²Considering the make up of the portfolio including the underlying portfolio of our private holdings of PPI and PTIF II, two private investees that themselves hold securities of public and/or private companies, the proportions of the total portfolio made up by publicly listed companies and private unlisted companies were 74.1% and 25.9%, respectively.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

1. Incorporation and nature of operations:

Pender Growth Fund Inc. (the "Company") was incorporated under the laws of British Columbia on March 7, 1994.

The Company has been managed by PenderFund Capital Management Ltd. (the "Manager") since 2003. The investment objective of the Company is to achieve long-term capital growth from investment in opportunities identified by the Manager.

The Company's registered office is located at 1830 - 1066 West Hastings Street, Vancouver, British Columbia, V6E 3X2.

2. Basis of preparation:

(a) Statement of compliance:

The annual financial statements of the Company are prepared under International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards ("IAS") Board. These condensed interim financial statements ("financial statements") of the Company have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. These financial statements should be read in conjunction with the audited annual financial statements.

The Company qualifies as an investment entity under IFRS 10, Consolidated Financial Statements.

These financial statements were authorized for issue by the Company's Board of Directors on May 26, 2023.

(b) Basis of measurement:

These financial statements have been prepared on a historical cost basis except for investments, which are measured at fair value.

(c) Functional and presentation currency:

These financial statements are presented in Canadian dollars, the Company's functional currency.

(d) Use of estimates and judgment:

The preparation of financial statements in conformity with IFRS requires the Manager to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized in the period in which the estimates are revised and in any future period affected.

The Company may hold financial instruments that are not quoted in an active market, including derivatives. The determination of the fair value of these investments is the area with the Manager's most significant accounting judgements and estimates in preparing these financial statements.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

3. Significant accounting policies:

These financial statements follow the same accounting policies and methods of application as applied in the December 31, 2022 annual audited financial statements.

4. Purchase of Pender Private Investments Inc.:

On May 28, 2021 (the "Effective Date"), the Company completed a transaction (the "WOF Transaction") with the Working Opportunities Fund (EVCC) Ltd. ("WOF"), an investment entity, for the acquisition of WOF's issued and outstanding shares pursuant to the April 7, 2021 definitive agreement (the "Arrangement Agreement"), under a plan of arrangement.

On the Effective Date of the WOF Transaction, the Company acquired 100% of WOF's Commercialization Series shares for a total cash purchase price of \$508,096 which was paid in full on closing and 97% of WOF's Venture Series shares for a total cash purchase price of \$25,316,232, 50% of which was paid on closing and 50% paid on November 25, 2021.

Under the terms of the WOF Transaction, PTF has an obligation to make certain additional payments to those former Venture Series shareholders that sold their shares (the "Exiting Shareholders") to PTF, for divestments of portfolio investments (the "Contingent Payment Obligation").

The divestment of two of PPI's portfolio investments triggered a requirement for a pro rata redemption of Legacy Shares at the NAV in effect at the time. In October 2021, PPI redeemed approximately 58.49% of all outstanding Legacy Shares, on a pro rata basis, at a redemption price of approximately \$6.4705 per share. Accordingly, the Company received a total of \$63,197,947 upon the redemption of 9,767,089 of the Legacy Shares it held. A portion of these proceeds was used to satisfy the additional cash payment to the Exiting Shareholders that was triggered by the divestments and the redemption: \$21,136,513 or \$1.2661 per share was paid effective October 13, 2021.

Because no letter of intent, term sheet or binding agreement for a divestment was entered into after November 18, 2021 and before February 18, 2022, which was the final period during which an additional exit payment could have been triggered, the right to any additional cash payment ceased and the Exit Venture Shares were redeemed automatically effective May 20, 2022.

In June 2022, in accordance with the terms of the Transaction, 10,440 Legacy Shares that weren't held in eligible accounts were purchased by the Company for a total payment of \$59,297, bringing its ownership of PPI to 98%.

On August 19, 2022, as provided by the Legacy Share right, PPI redeemed a portion of its Legacy Shares. The redemption was triggered by certain divestments of PPI's portfolio companies. Accordingly, PPI redeemed approximately 7.04% of all outstanding Legacy Shares on a pro rata basis, at a redemption price of approximately \$8.2573 per share. The Company received a total of \$4,033,749 upon the redemption of 488,507 of the Legacy Shares it held. As at March 31, 2023, the Company held 98% (December 31, 2022, 98%) of the outstanding Legacy Shares, or 6,452,726 Legacy Shares (December 31, 2022 - 6,452,726 Legacy shares).

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

4. Purchase of Pender Private Investments Inc. (continued):

Under IFRS, the gain inherent in the difference between the purchase price paid by the Company and the fair value of the assets it acquired is treated as a deferred gain and contra asset under the investments reported in the Statements of Financial Position. On the effective date of the WOF Transaction, a \$32,798,793 deferred gain was recorded by the Company. The deferred gain is being recognized to the extent that it arises from a change in a factor (including time) that market participants would take into account when pricing the investment. For the three months ended March 31, 2023, the Company recognized \$1,260,763 deferred gain (March 31, 2022 - \$Nil). As at March 31, 2023, the total deferred gain recognized since 2021 was \$28,915,371 (December 31, 2022, \$27,654,608), the remaining balance was \$3,883,422 (December 31, 2022 - \$5,144,185).

5. Related party transactions:

- (a) Management and performance fees:
 - (i) Management fees:

In accordance with the Third Amended and Restated Management Agreement dated May 1, 2017, as amended March 7, 2019 (the "Management Agreement"), the Manager provides management services in connection with all aspects of the identification, investment, development, active monitoring and ultimate divestment of all investments of the Company. This Management Agreement is in effect until April 30, 2023 and shall be renewed automatically at that date for an additional four-year term, unless a vote of shareholders determines otherwise.

In exchange for these management services, the Company pays a management fee. Effective May 2019, the management fee was set at 2.50% of the first \$15,000,000 of the value of Net Assets and 1.75% of the value of Net Assets above \$15,000,000.

The management fee is calculated and paid monthly. Net assets used in the management fee calculation exclude the value of the Company's investment in PPI, which is also managed by the Company's Manager. For the three months ended March 31, 2023, the management fees incurred by the Company were \$169,397 (March 31, 2022 - \$240,065).

(ii) Performance fees:

The Manager is entitled to a performance fee plus applicable taxes in certain circumstances, based on achieving performance criteria set out in the Management Agreement. The performance fee is calculated on an annual basis as 20% of any net increase in shareholders' equity above an annual hurdle rate of 6%. The performance fee is subject to a high water mark, being the year-end total shareholders' equity per share for the most recent preceding year in which a performance fee was earned. Subject to accumulation of the hurdle rate in years in which no performance fee is payable and the recalculation discussed in section (iii) below, the high water mark will not be reset other than to be adjusted in the event of a subdivision or consolidation of the shares. Performance fees are accrued during the year, where applicable. However, annual performance fees are calculated on the last valuation date of the year and are payable to the Manager each year upon publication of the Company's audited annual financial statements. For the three months ended March 31, 2023, the Company accrued performance fees of \$Nil (December 31, 2022 - \$Nil).

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

5. Related party transactions (continued):

- (a) Management and performance fees (continued):
 - (iii) Performance fees 2021:

In 2021, the performance fee expense of \$27,743,466 comprised \$22,514,596 that arose from the net increase in unrealized appreciation of the Company's direct and indirect holdings of Copperleaf ("2021 Unrealized Performance Fee") and \$5,228,870 that arose from net realized gains and this latter amount was paid to the Manager in April 2022.

The Manager, in its sole discretion, decided that the 2021 Unrealized Performance Fee would not be paid upon the publication of the Company's audited annual financial statements, instead it would be recalculated and the accrual and expenses adjusted accordingly, and quarterly payments would be triggered from time to time as gains are realized. The quarterly payments would be equal to the total recalculated performance fee arising from (1) the realized gain on the Company's direct holdings of Copperleaf and (2) the realized gain on the Company's indirect holdings of Copperleaf in excess of 20% of the Company's shareholders' equity at such time. After the Copperleaf holdings in excess of a 20% weighting are sold, the performance fee on the unrealized appreciation on the Company's remaining holdings of Copperleaf will be paid. The high water mark will be recalculated accordingly.

As at March 31, 2023, the total performance fee payable in this respect was \$3,542,359 (December 31, 2022 - \$4,249,712), which comprised \$13,242 arising from net realized gains on Copperleaf shares and \$3,529,117 arising from the net unrealized appreciation of the Company's direct and indirect holdings of Copperleaf.

For the year ended December 31, 2022, the high water mark was \$11.17 excluding unrealized gains on Copperleaf. As at March 31, 2023 the high water mark was adjusted to \$11.20 reflecting net realized gains on Copperleaf during the period. As at March 31, 2023, the portion of the high water mark that relates to the net unrealized appreciation of the Company's direct and indirect holdings of Copperleaf was \$2.94 (December 31, 2022 - \$3.32).

During the three months ended March 31, 2023, due to a change in the unrealized appreciation of Copperleaf and realized gains on Copperleaf shares sold, the Company recorded a net reversal of previously accrued performance fees of \$425,968 (March 31, 2022 – \$9,003,263).

2021 performance fee					
For the three months ended March 31, 2023	Balance, beginning of period	Change in unrealized appreciation	Realized gain (unpaid)	Realized gain (paid)	Balance, end of period
Performance fees Fees waived by the	7,409,239	(2,328,572)	17,656	(375,180)	4,723,143
Manager	(3,159,527)	1,889,362	(4,414)	93,795	(1,180,784)
Net amount	4,249,712	(439,210)	13,242	(281,385)	3,542,359

The changes related to the March 31, 2023 performance fee accrual are outlined in the table below:

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

5. Related party transactions (continued):

- (a) Management and performance fees (continued):
 - (iv) PPI Performance Fee:

In certain circumstances, the Manager also earns a performance fee by virtue of its management of PPI (the "PPI Performance Fee"). Because the Company currently holds 98% of PPI, the Manager in its sole discretion decided to pay the Company 98% of the PPI Performance Fee. As at March 31, 2023, the Company had accrued a receivable from the Manager for this in the amount of \$7,150,019 (December 31, 2022 - \$7,480,711).

(v) Performance fee summary:

2021 total performance

For the three months ended March 31, 2023, the net impact of the adjustments (recovery) described in notes 5(a)(iii) and (iv) above was (\$3,607,660) (December 31, 2022 – (\$3,230,999)), as summarized in the table below:

For the three months ended March 31, 2023	Balance, beginning of period	Changes	Paid/ payment received	Balance, end of period
Net amount of performance fee Amount due from Manager related to performance fees earned from PPI –	4,249,712	(425,968)	(281,385)	3,542,359
Unrealized appreciation	(7,480,711)	330,692	-	(7,150,019)
Total performance fee				v i i
adjustment	(3,230,999)	(95,276)	(281,385)	(3,607,660)

(b) Due from related parties:

As at March 31, 2023, the Company had a net balance due from related parties of \$3,496,336 (December 31, 2022 – \$3,023,368), all of which was due from the Manager. Of this amount, \$3,653,683 was due to the Manager including 2021 performance fees of \$3,542,359, as described in note 5(a)(iii) and management fees and operating expenses \$111,324 paid by the Manager on behalf of the Company. This was offset by an amount of \$7,150,019 due from the Manager (December 31, 2022 - \$7,480,711) for PPI Performance Fees that the Manager agreed to pay to the Company, as described in note 5(a)(iv) above.

(c) Share holdings:

As at March 31, 2023, the Manager, directors and officers of the Company directly or indirectly held 11.6% (December 31, 2022 – 11.6%) of the Company's Class C Shares. The aggregate investment by the Company's directors and officers in all Portfolio Companies did not exceed 1.0% of the issued and outstanding shares of any Portfolio Company.

As previously noted, the Company holds 98% of the outstanding shares of PPI, an entity also managed by the Manager.

The Company has a commitment to invest \$12,500,000 in PTIF II, a limited partnership managed by a related entity. As at March 31, 2023, the Company had invested \$1,746,406 under the first capital call (13.97% of its total capital commitment) and the unfunded balance is \$10,753,594. PTIF II invests in a concentrated portfolio of business to business and health-focused technology companies at their inflection point.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

6. Securities lending transactions:

As at March 31, 2023 and December 31, 2022, the Company did not have any securities loaned and collateral received. There was no securities lending income earned for the three month ended March 31, 2023 and 2022.

7. Withholding tax expense:

Certain dividend income received by the Company is subject to withholding tax imposed in the country of origin. During the year, withholding tax rates were between 0% and 35% (2022 – between 0% and 35%).

8. Share capital:

(a) Authorized share capital:

As at March 31, 2023, the authorized capital of the Company consists of:

- (i) An unlimited number of Class C Participating Common Shares ("Class C Shares"); and
- (ii) An unlimited number of Preferred Shares ("Preferred Shares").

Class C Shares:

Class C Shares are not redeemable or convertible. Class C Shares are listed on the TSX Venture Exchange ("TSXV") under the ticker symbol "PTF". Each Class C Share is entitled to one vote in any vote on shareholder matters and is entitled to dividends at the discretion of the Board of Directors.

Preferred Shares:

The Preferred Shares were created on July 24, 2019. As at March 31, 2023 and December 31, 2022, no Preferred Shares have been issued. The special rights and restrictions of the Preferred Shares empower the Board to fix the number of shares in each series of each class of Preferred Shares and to fix the preferences, special rights and restrictions, privileges, conditions and limitations attaching to the shares of that series, before the issuance of shares of any particular series. The Board has the power to fix, among other things, the number of shares constituting any series, the voting powers, designation, preferences and relative participation, optional or other special rights and dividend rate, terms of redemption (including sinking fund provisions), redemption price or prices, conversion rights and liquidation preferences of the shares constituting any series. The issuance of Preferred Shares could affect the rights of the holders of Class C shares.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

8. Share capital:

(b) Issued and fully paid shares:

During the years ended March 31, 2023 and 2022, the Company has issued and fully paid Class C shares outstanding as follows:

	Balance, Beginning of period	Shares issued	Shares repurchased	Balance, end of period
March 31, 2023 Class C	7,569,929	-	(16,300)	7,553,629
March 31, 2022 Class C	7,616,529	-	(21,300)	7,595,229

On February 14, 2022, the Company refiled its NCIB on the TSXV. Upon launch, the Company had 7,609,621 shares issued, of which 6,788,397 shares represented its public float. The Company is entitled to purchase up to a maximum of 678,839 shares, representing 10% of its public float, over the one-year period of this NCIB. The NCIB will continue until February 13, 2023, unless terminated earlier in accordance with its terms.

On February 14, 2023, the Company renewed its NCIB on the TSXV. Upon launch, the Company had 7,568,921 shares issued, of which 6,630,459 shares represented its public float. The Company is entitled to purchase up to a maximum of 663,045 shares, representing 10% of its public float, over the one-year period of this NCIB. The NCIB will continue until February 13, 2024, unless terminated earlier in accordance with its terms. The Company intends to continue to repurchase its shares under the NCIB where the shares are trading at a price that is less than what we see as their intrinsic value, in order to enhance shareholder value.

During the three months ended March 31, 2023, the Company bought back 16,300 shares under its NCIB for a total price of \$118,610 (March 31, 2022 – 21,300 shares and \$335,644).

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

8. Share capital:

(c) Equity capital:

The changes in shareholders' equity for the three months ended March 31, 2023 and 2022 are as follows:

	Share capital	Retained earnings	Total
Balance, January 1, 2023	\$ 17,442,542	\$ 52,796,713	\$ 70,239,255
Net loss	-	(3,293,058)	(3,293,058)
Capital transactions	(118,610)	-	(118,610)
Balance, March 31, 2023	\$ 17,323,932	\$ 49,503,655	\$ 66,827,587

	Share capital	Retained earnings	Total
Balance, January 1, 2022	\$ 18,007,980	\$ 180,635,675	\$ 198,643,655
Net loss	-	(51,821,705)	(51,821,705)
Capital transactions	(335,644)	-	(335,644)
Balance, March 31, 2022	\$ 17,672,336	\$ 128,813,970	\$ 146,486,306

9. Capital management:

The Company's Class C Shares represent the capital of the Company. The Company is not subject to any external or internally imposed restrictions on its capital other than debt covenants as described in Note 10.

The investment objective of the Company is to achieve long-term capital growth. The firm invests in public and private companies based primarily in Canada and the U.S., principally in the technology sector.

The Company's objective in managing capital is to ensure it has the ability to continue to make new investments and to make follow-on investments in companies that it has previously invested in, to have sufficient cash for operations and to continue to operate as a going concern.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

10. Loan payable:

In connection with the WOF Transaction described in Note 4, the Company obtained a three-year term loan from a Canadian chartered bank ("Bank"), under a loan agreement dated May 28, 2021, as amended March 31, 2022. The facility provided for a maximum amount of \$10,000,000 to be advanced in one or two tranches (the "Term Loan"). As security for the Term Loan, the Company granted the lender a security interest in all of the shares of PPI held by the Company and its holdings in its public company investments.

On March 31, 2022, the bank swept the \$5,000,000 owing under this first tranche. Concurrently, the Company drew down \$5,000,000 as a second tranche, which bears interest at the rate of Prime plus 2% for a minimum one year term. Starting from November 1, 2022, the Company was required to make monthly principal repayments of \$250,000. The Term Loan matures on May 28, 2024. As at March 31, 2023, the balance owing under the Term Loan was \$3,750,000.

11. Financial risk management:

The Company may be exposed to various financial risks in the normal course of business, associated with its investment objectives and strategies, financial instruments and the markets in which it invests. These risks include credit risk, liquidity risk, and market risk which consists of currency risk, interest rate risk and other price risk.

The Company's investment objective is to achieve long-term capital growth by investing in public and private companies. The Company maintains positions in a variety of financial instruments in accordance with its investment objectives and strategies. The Schedule of Investment Portfolio groups these investment holdings by asset type. The Company's exposure to financial risk is concentrated in its investment holdings. The Manager manages the potential impact of these financial risks on the Company's performance by employing and overseeing professional and experienced portfolio advisors who regularly monitor the Company's positions and market events and diversify the investment portfolio within the constraints of the investment guidelines.

The economic uncertainties around persistent inflation pressure, bank failures, geopolitical events and the lingering COVID-19 pandemic continue to impact the global economy.

During the first quarter, the collapse of Silicon Valley Bank and Signature Bank led to an overall financial market decline especially in the banking sector. The Company does not have any direct exposure to the banks and is monitoring its portfolio value given the impact of the situation across the broader financial sector.

Future developments in these challenging areas could impact the Company's results and financial condition and the full extent of that impact remains unknown. Developing reliable estimates and applying judgment continue to be substantially complex. Actual results may differ from those estimates and assumptions.

The Company will continue to support its Portfolio Companies, to monitor the impact that global events have on them and to reflect the consequences as appropriate in its accounting and reporting.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

11. Financial risk management (continued):

The Company's exposure to financial risks is concentrated in its investment holdings. The Company carries out part of its investment strategy by investing in related entities such as PPI and PTIF II. The financial risks associated with the Company's investment strategy are disclosed based on its direct holdings. The Manager's risk management practices include the monitoring of compliance with investment objectives and strategies. The Manager manages the potential effects of these financial risks on the Company's performance by regularly monitoring each position and market and global events and by diversifying investment portfolios within the constraints of the Company's investment objective.

(a) Credit risk:

Credit risk represents the risk associated with the inability of a counterparty to fulfill its financial obligations. The Company limits its exposure to credit risk related to its excess cash, when applicable, by investing in high quality short-term investments, typically term or other deposits with a large Canadian bank.

The Company is also exposed to credit risk through its investment in loans, convertible and other notes and preferred shares of its investee companies. The Company manages this credit risk through careful selection and monitoring of its investee companies. Receivables relating to the Company's investments are also subject to credit risk and are managed through active review of the portfolio of private unlisted investments.

The Company's maximum exposure to credit risk as at March 31, 2023 was \$11,650,207 (December 31, 2022 - \$14,025,031).

(b) Liquidity risk:

Liquidity risk is the risk that the Company may not be able to settle or meet its obligations on time or at a reasonable price. The Company invests in equity securities and other financial instruments. A portion of the Company's equity holdings are in private unlisted investments for which no active markets exist. Accordingly, timely disposition may not be possible, and the realized price may be significantly different from the carrying value.

The Company's policy is to maintain sufficient cash to meet normal operating requirements. It is also the Company's policy that the Manager monitors the Company's liquidity position and that the board of directors reviews it on a quarterly basis.

The following table summarizes the Company's financial liabilities as at March 31, 2023 and December 31, 2022, based on undiscounted contractual cash flows:

	Mar	ch 31, 2023	Decem	ber 31, 2022
Interest payable Payable for investments purchased Share repurchase payable Accounts payable and accrued liabilities Loan payable	\$	27,709 28,356 21,080 172,383 3,750,000	\$	31,864 13,186 142,880 4,500,000
Total	\$	3,999,528	\$	4,687,930

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

11. Financial risk management (continued):

(c) Market risk:

Market risk is the risk that changes in market prices, such as interest rates, foreign exchange rates and equity prices, will affect the Company's income or the fair value of its holdings of financial instruments. These changes present the risk that markets as a whole may go down in value, including the possibility that markets may go down sharply and unpredictably at times. The value of most investments, and in particular equity securities, is affected by changes in general market conditions. These changes may be caused by corporate developments, general market sentiment, changes in interest rates, changes in the level of inflation, political and economic changes both domestic and foreign, catastrophic events, such as pandemics and outbreaks of disease, natural disasters including those exacerbated by climate change, war, acts of aggression or terrorist events, and other unforeseen events that may cause changes to markets.

(i) Interest rate risk:

Interest rate risk is the risk that fair value of a financial instrument will fluctuate because of changes in market interest rates. The Company's investment portfolio may contain private debt instruments, the majority of which may be convertible. The valuation of these private debt instruments is based on the enterprise value of the underlying Company and generally does not change with changes in market interest rates. The interest rates of these instruments are fixed, so changes in market interest rates will not impact cash flows of the Company.

(ii) Currency risk:

Currency risk is the risk that the fair value of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company invests primarily in Canadian securities. Accordingly, the Company is not subject to significant currency risk.

(iii) Other price risk:

Other price risk is the risk that the fair value of a financial instrument will fluctuate as a result of changes in market prices (other than those arising from the aforementioned risks), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in a market. The Manager manages other price risk through careful selection of investments and through diversification of the investment portfolio.

As at March 31, 2023, if the fair value of the Company's publicly listed investments had increased or decreased by 10% with all other factors remaining constant, the Company's shareholders' equity would have increased or decreased by approximately \$1,246,000 (December 31, 2022 - \$1,164,000). Price sensitivity was determined based on portfolio-weighted beta. In practice, actual results may differ from this sensitivity analysis and the difference could be material.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

12. Fair value of financial instruments:

(a) Valuation models:

The fair values of financial assets and financial liabilities that are traded in active markets are based on quoted market prices. For all other financial instruments, the Company determines fair values using other valuation techniques.

For financial instruments that trade infrequently and have little price transparency, fair value is less objective, and requires varying degrees of judgment depending on liquidity, concentration, uncertainty of market factors, pricing assumptions and other risks affecting the specific instrument.

The Company measures fair value using the following fair value hierarchy that reflects the significance of the inputs used in making the measurements.

- Level 1: inputs that are quoted market prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.
- Level 2: inputs other than quoted prices included within Level 1 that are observable either directly (i.e. prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company uses widely recognized valuation models for determining the fair value of common and relatively simple financial instruments, such as debt securities, mutual fund units and warrants that use only observable market data and require little management judgment and estimation. Observable prices and model inputs are usually available in the market for listed debt and equity securities, exchange-traded derivatives and simple OTC derivatives such as forward foreign currency contacts. The availability of observable market prices and model inputs reduces the need for management judgment and estimation, and reduces the uncertainty associated with the determination of fair values. The availability of observable market prices and inputs, which are prone to change based on specific events and general conditions in the financial markets, varies depending on the products and markets.

For more complex instruments, the Company uses recognized valuation models. Some or all of the significant inputs into these models may not be observable in the market and may be derived from market prices or rates or estimated based on assumptions. Valuation models that employ significant unobservable inputs require a higher degree of management judgment and estimation in the determination of fair value.

In determining fair value for these types of instruments the Manager considers: the history and nature of the business; operating results and financial conditions; the general economic, industry and market conditions; capital market and transaction market conditions; independent valuations of the business; contractual rights relating to the investment; comparable trading and transaction multiples, where applicable; and other pertinent considerations. Adjustments to the carrying value of the investments may also be determined by the Manager when there is pervasive and objective evidence of a decline in the value of the investment, as indicated by an assessment of the financial condition of the investment based on operational results, forecasts and other developments since acquisition.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

12. Fair value of financial instruments (continued):

(b) Fair value hierarchy - financial instruments measured at fair value:

The table below presents the fair value of financial instruments as at March 31, 2023 and December 31, 2022 by the level in the fair value hierarchy into which the fair value measurement is categorized. The amounts are based on the values recognized in the Statements of Financial Position.

	March 31, 2023	December 31, 2022
Level 1: Publicly listed companies	\$ 9,551,215	\$ 9,727,864
Level 2: Publicly listed companies	-	-
Level 3: Publicly listed companies – loans Private unlisted companies	- 52,392,987	800,000 55,771,675
Total Level 3	52,392,987	56,571,675
	\$ 61,944,202	\$ 66,299,539

During the three months ended March 31, 2023, no transfers from level 3 to level 1 of the fair value hierarchy upon becoming publicly traded.

The following table shows a reconciliation of movements in the fair value of financial instruments categorized within Level 3 for the three months ended March 31, 2023 and December 31,2022:

	March 31, 2023	December 31, 2022
Opening balance Amounts paid on purchase of investments Sales and settlements of investments Transfers between Level 1 and Level 3 Total loss recognized in comprehensive income	\$ 56,571,675 1,500,174 (2,211,193) - (3,467,669)	\$ 157,817,928 12,332,042 (7,831,780) - (105,746,515)
Ending balance	\$ 52,392,987	\$ 56,571,675

Included in the net change in unrealized appreciation (depreciation) in fair value of investments on the Statements of Comprehensive Income for the three months ended March 31, 2023 is a change in unrealized depreciation of \$3,467,669 (December 31, 2022 – unrealized appreciation \$104,036,114 related to Level 3 investments.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

12. Fair value of financial instruments (continued):

(c) Significant unobservable inputs used in measuring fair value:

The table below sets out information about significant unobservable inputs used at March 31, 2023 and December 31, 2022 in measuring financial instruments categorized as Level 3 in the fair value hierarchy.

Description	Fair value	Valuation technique	Unobservable input	Revenue multiple	Sensitivity to change in significant unobservable input
Unlisted private investments	\$9,817,160	Market approach	Revenue multiple	\$9,817,160	The estimated fair value would increase if revenue multiple increased
December 31, 2	022				
Description	Fair value	Valuation technique	Unobservable input	Revenue multiple	Sensitivity to change ir significan unobservable inpu
-					

Significant unobservable inputs are developed as follows:

(i) Revenue multiple:

Revenue multiples are selected from comparable public companies based on geographic location, industry, size, target markets, and other factors that the Manager considers to be reasonable. The traded multiples for the comparable companies are determined by dividing the enterprise value of the company by its revenue.

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

12. Fair value of financial instruments (continued):

(d) Effects of unobservable input on fair value measurement:

Although the Company believes that its estimates of fair value are appropriate, the use of different methodologies or assumptions could lead to different measurements of fair value. For fair value measurements in Level 3, changing one or more of the assumptions used to alternative reasonably possible assumptions would have the following effects on shareholders' equity as at March 31, 2023 and December 31, 2022:

	Marc	March 31, 2023		December 31, 2022	
Favourable Unfavourable	\$	981,716 (981,716)	\$	505,532 (505,532)	

The favourable and unfavourable effects of using alternative reasonably possible assumptions for the valuation of unlisted private investments have been calculated by recalibrating the model values using unobservable inputs based on ranges of possible estimates.

(e) Financial instruments not measured at fair value:

The carrying value of the Company's financial instruments, other than investments, approximates their fair value given their short-term nature. These financial instruments are classified as Level 2 in the fair value hierarchy because while prices are available, there is no active market for these instruments.

13. Income taxes:

The taxation year-end of the Company is December 31. As at the end of the 2022 tax year-end, the Company had non-capital losses of \$6,243,996 (2021 - \$Nil) and capital losses of \$14,180,878 (2021 - \$Nil) available for carryback to the 2022 tax year, including non-capital losses of \$5,882,132 and capital losses of \$14,180,878.

As of March 31, 2023, the Company's income taxes receivable balance was \$3,502,595 (December 31, 2022 - \$3,502,595). The remaining 2022 non-capital losses of \$361,864 are available for carry forward to future years up to a maximum of 20 years.

As at March 31, 2023, the deferred income tax liability was \$872,402 (December 31, 2022 - \$1,536,825).

Notes to the Condensed Interim Financial Statements (Unaudited)

Three months ended March 31, 2023

14. Involvement with subsidiaries and associates:

The table below describes subsidiaries and associates in which the Company holds an interest and that it does not consolidate or account for by the equity method.

Entity	Nature and purpose	Interest held by the Company	
Pender Private Investments Inc.	Private Equity Investments	Investment in common shares	
Pender Technology Inflection Fund II Limited Partnership	Private Equity Investments	Investment in limited partnership	

The table below sets out interests held by the Company in unconsolidated subsidiaries and associates. The maximum exposure to loss is the carrying amount of the financial assets held.

March 31, 2023 and December 31, 2022						
Name of Entity	Relationship	Principal place of business	Country of incorporation	Ownership interest	Voting rights	
Pender Private Investments Ir	nc. Subsidiary	Canada	Canada	98% (2022 - 98%)	98% (2022 - 98%)	
Pender Technology Inflection Fund II Limited Partnership	Partnership	Canada	Canada	25% (2022 – 25%)	N/A	

Furthermore, none of the subsidiaries described in the table above are subject to any restrictions.

15. Subsequent event:

On April 19, 2023, the Company and the Bank agreed to amend the terms of the Credit Agreement. On May 1, 2023, the Company made a one-time principal repayment of \$1,000,000, which reduced the remaining loan balance to \$2,500,000.

On April 30, 2023, the Management Agreement was renewed automatically for a further term of four years, until April 30, 2027.

On April 21, 2023, PPI redeemed approximately 2.4% of the outstanding Legacy Shares on a pro-rata basis at a redemption price of approximately \$6.39 per share. The Company received a total of \$1,003,457 for the 157,122 of its Legacy Shares that were redeemed. Subsequent to this redemption the Company held 98% of the outstanding Legacy Shares, or 6,295,604 Legacy Shares.

On May 23, 2023, PTF and PPI signed a non-binding letter of intent for PTF to purchase all of PPI's Legacy Shares that are held by the 2% minority shareholders (the "Minority Shareholders"). It is proposed that PTF acquires the shares held by the Minority Shareholders under a plan of arrangement, at a price equal to 100% of the NAV in effect five business days before the execution of the definitive agreement (the "Purchase Price"). The Purchase Price will be recalculated five business days prior to the closing of the proposed transaction and will be adjusted up or down to a maximum of five percent based on the updated calculation. Completion of the proposed transaction remains subject to, among other things, the negotiation of a definitive agreement, approval of the PPI shareholders (including majority of the minority approval), receipt of a satisfactory Fairness Opinion and court approval.